Mather Group’s BridgeBio Pharma BBIO Stock Holding History

Mather Group’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-70	Closed	-$3.64K	–	743
2025 Q3	$3.64K	Buy	+70	New	+$3.41K	﹤0.01%	1453

Other funds holding BBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mather Group's BBIO Position: Q4 2025 in Review

Mather Group sold out of BridgeBio Pharma (BBIO) in Q4 2025, closing a stake of 70 shares — an estimated $3.64K sold.

Mather Group first reported a position in BBIO in Q3 2025 and held it in 1 quarter. The position peaked at $3.64K in Q3 2025. 433 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

Mather Group reported no remaining BridgeBio Pharma position as of Q4 2025 after selling out during the quarter.
Mather Group sold 70 BridgeBio Pharma shares in Q4 2025, an estimated $3.64K.
Mather Group first reported a position in BridgeBio Pharma in Q3 2025 and held it in 1 quarter.
Mather Group's BridgeBio Pharma position peaked at $3.64K in Q3 2025.
433 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on Mather Group's 13F filing for Q4 2025, filed 13 Jan 2026.